Oppenheimer downgraded Astria Therapeutics (ATXS) to Perform from Outperform without a price target after the company reached an agreement to be acquired by BioCryst (BCRX) for cash and stock at an implied value of $13 per share, or $700M.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- BioCryst weakness presents ‘compelling’ buying opportunity, says RBC
- Strategic Acquisition of Astria Therapeutics by BioCryst Pharmaceuticals Highlights Potential of Navenibart for HAE Prophylaxis
- BioCryst price target raised to $15 from $14 at Jefferies
- Hold Rating on BCRX Amid Strategic Acquisition of Astria Therapeutics and Market Challenges
- Astria Therapeutics downgraded to Hold from Buy at Jefferies